NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-909-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.10 billion
Profitability
Miscellaneous
Employees2,600
Next Earnings Date7/30/2019 (Estimated)
OptionableOptionable
NuVasive (NASDAQ:NUVA) Frequently Asked Questions
What is NuVasive's stock symbol?
NuVasive trades on the NASDAQ under the ticker symbol "NUVA."
How will NuVasive's stock buyback program work?
NuVasive announced that its Board of Directors has approved a stock buyback program on Wednesday, October 25th 2017, which allows the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.
How were NuVasive's earnings last quarter?
NuVasive, Inc. (NASDAQ:NUVA) announced its earnings results on Wednesday, May, 1st. The medical device company reported $0.53 EPS for the quarter, topping the Zacks' consensus estimate of $0.41 by $0.12. The medical device company had revenue of $274.78 million for the quarter, compared to the consensus estimate of $269.22 million. NuVasive had a net margin of 4.39% and a return on equity of 15.16%. NuVasive's revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.39 EPS. View NuVasive's Earnings History.
When is NuVasive's next earnings date?
What guidance has NuVasive issued on next quarter's earnings?
NuVasive updated its FY19 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of $2.20-2.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.25. The company issued revenue guidance of $1.14-1.16 billion, compared to the consensus revenue estimate of $1.15 billion.
What price target have analysts set for NUVA?
14 analysts have issued 12 month target prices for NuVasive's shares. Their predictions range from $42.00 to $82.00. On average, they expect NuVasive's stock price to reach $66.9231 in the next year. This suggests a possible upside of 16.0% from the stock's current price. View Analyst Price Targets for NuVasive.
What is the consensus analysts' recommendation for NuVasive?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 2 sell ratings, 5 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NuVasive.
What are Wall Street analysts saying about NuVasive stock?
Here are some recent quotes from research analysts about NuVasive stock:
- 1. Cantor Fitzgerald analysts commented, ": We maintain our Neutral rating on NUVA, but raise our 12- month PT to $61 from $50 as NUVA’s performance justifies multiple expansion. NUVA reported 1Q revenue of $274.8MM (+5.9% organic), beating FactSet consensus by $5.6MM. 40bp benefit from one-time NCS collections and a faster-than-expected benefit from West Carrollton, GM (72.9%) and OM (14.9%) were higher than expectations, driving an EPS beat of $0.12. A number of favorable one-time items make determining the true underlying performance challenging." (5/2/2019)
- 2. According to Zacks Investment Research, "Robust sales figures in international markets buoy optimism. We are upbeat about the strong demand for several of the company’s recently-launched products in the U.S. Spinal Hardware business. Furthermore, NuVasive's latest receipt of 510(k) clearance from the FDA along with the CE mark approval for its Precice Bone Transport System looks encouraging. On the flip side, headwinds like pricing pressure, reimbursement issues and a competitive landscape are major downsides. Overall, NuVasive has underperformed its industry over the past six months." (4/23/2019)
- 3. Needham & Company LLC analysts commented, "NUVA’s 3Q18 revenue beat while its EPS missed. Management raised revenue guidance but lowered EPS guidance. Organic growth increased to 8% in 3Q18 from 5% in 2Q18 as improved domestic growth offset slower international growth. Operating margin was 220 bps below consensus as management decided to exploit an improving spine market by reinvesting in SG&A (up 70 bps Y/Y) and R&D (up 50 bps Y/Y). Gross margin met consensus and West Carrollton remains on track to deliver 130-150 bps of margin benefit in 2019. While the margin performance is frustrating, we expect the stronger growth combined with in-sourcing to drive better margin performance in 2019 and reiterate our Buy rating." (10/31/2018)
Has NuVasive been receiving favorable news coverage?
Media headlines about NUVA stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NuVasive earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned media coverage about the medical device company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for NuVasive.
Who are some of NuVasive's key competitors?
Some companies that are related to NuVasive include ABIOMED (ABMD), Insulet (PODD), Hill-Rom (HRC), Haemonetics (HAE), Novocure (NVCR), Penumbra (PEN), ICU Medical (ICUI), Integra Lifesciences (IART), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Merit Medical Systems (MMSI), Cantel Medical (CMD), Glaukos (GKOS), Irhythm Technologies (IRTC) and Nevro (NVRO).
What other stocks do shareholders of NuVasive own?
Who are NuVasive's key executives?
NuVasive's management team includes the folowing people:
- Mr. J. Christopher Barry, CEO & Director (Age 46)
- Mr. Matthew W. Link, Pres (Age 44)
- Dr. Peter M. Leddy, Exec. VP of People & Culture (Age 56)
- Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 52)
- Mr. Jereme Sylvain, Chief Accounting Officer (Age 39)
Who are NuVasive's major shareholders?
NuVasive's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Champlain Investment Partners LLC (4.38%), Victory Capital Management Inc. (1.74%), Anchor Capital Advisors LLC (1.58%), Primecap Management Co. CA (1.57%), Eagle Asset Management Inc. (1.31%) and Stephens Investment Management Group LLC (1.22%). Company insiders that own NuVasive stock include Gregory T Lucier, Lesley H Howe, Matthew Link and Peter Michael Leddy. View Institutional Ownership Trends for NuVasive.
Which major investors are selling NuVasive stock?
NUVA stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Rothschild & Co. Asset Management US Inc., Carillon Tower Advisers Inc., Champlain Investment Partners LLC, Fort Washington Investment Advisors Inc. OH, Rice Hall James & Associates LLC, Anchor Capital Advisors LLC and DNB Asset Management AS. View Insider Buying and Selling for NuVasive.
Which major investors are buying NuVasive stock?
NUVA stock was acquired by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Sector Gamma AS, Hussman Strategic Advisors Inc., Boston Advisors LLC, State of Wisconsin Investment Board, Dupont Capital Management Corp, ARP Americas LP and Motley Fool Asset Management LLC. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.
How do I buy shares of NuVasive?
Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NuVasive's stock price today?
One share of NUVA stock can currently be purchased for approximately $57.69.
How big of a company is NuVasive?
NuVasive has a market capitalization of $2.99 billion and generates $1.10 billion in revenue each year. The medical device company earns $12.47 million in net income (profit) each year or $2.23 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.View Additional Information About NuVasive.
What is NuVasive's official website?
How can I contact NuVasive?
NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]
MarketBeat Community Rating for NuVasive (NASDAQ NUVA)
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
